PDCD1 and neoplasm: Ipilimumab and nivolumab are CTLA4 and PD-1 inhibitors, respectively, and can enhance an inflammatory response by reversing the cancer immunosuppressant environment, also enhancing the natural killer (NK) cell activation against the tumour.35,36